Английская Википедия:Atogepant
Шаблон:Short description Шаблон:Use American English Шаблон:Use dmy dates Шаблон:Cs1 config Шаблон:Infobox drug
Atogepant, sold under the brand name Qulipta among others, is a medication used to prevent migraines.[1][2] It is a gepant, an orally active calcitonin gene-related peptide receptor antagonist.[1][3]
The most common side effects include nausea (feeling sick), constipation, tiredness, somnolence (sleepiness), decreased appetite, and decreased weight.[2]
Atogepant was approved for medical use in the United States in September 2021,[1][4] and in the European Union in August 2023.[2][5]
Medical Uses
Atogepant is indicated for the preventive treatment of episodic migraine in adults.[1][2]
In the European Union, atogepant (Aquipta) is indicated for prophylaxis (prevention) of migraine in adults who have at least four migraine days per month.[2]
History
The benefits and side effects of atogepant were evaluated in two clinical trials of 1,562 participants with a history of migraine headaches occurring on 4 to 14 days per month.[6] The two trials to show the benefits were designed similarly.[6] Trials 1 and 2 assigned participants to one of several doses of atogepant or placebo daily for three months.[6] Neither the participants nor the health care providers knew which treatment was being given until after the trial was completed.[6] The benefit of atogepant was assessed based on the change from baseline in the number of migraine days per month to the last month of the three-month treatment period, comparing participants in the atogepant and placebo groups.[6] The trials were conducted at over 100 sites in the United States.[6] The safety of atogepant was evaluated in 1,958 participants with migraine who received at least one dose of atogepant; therefore, the number of participants representing efficacy findings may differ from the number of participants representing safety findings due to different pools of study participants analyzed for efficacy and safety.[6]
Research
A study found that atogepant reduced the number of migraine days over twelve weeks.[7]
References
Шаблон:Antimigraine preparations Шаблон:Portal bar
- ↑ 1,0 1,1 1,2 1,3 Шаблон:Cite web
- ↑ 2,0 2,1 2,2 2,3 2,4 Ошибка цитирования Неверный тег
<ref>; для сносокAquipta EPARне указан текст - ↑ Шаблон:Cite journal
- ↑ Шаблон:Cite press release
- ↑ Шаблон:Cite press release
- ↑ 6,0 6,1 6,2 6,3 6,4 6,5 6,6 Шаблон:Cite web Шаблон:PD-notice
- ↑ Шаблон:Cite journal
- Английская Википедия
- Drugs developed by AbbVie
- Antimigraine drugs
- Calcitonin gene-related peptide receptor antagonists
- Carboxamides
- Organofluorides
- Piperidines
- Pyridines
- Pyrroles
- Spiro compounds
- Страницы, где используется шаблон "Навигационная таблица/Телепорт"
- Страницы с телепортом
- Википедия
- Статья из Википедии
- Статья из Английской Википедии
- Страницы с ошибками в примечаниях
